| Document Date: 2013-05-01 14:24:34
Open Document File Size: 53,76 KBShare Result on Facebook
City RARITAN / / Company Janssen Pharmaceutical Companies / Janssen Research & Development LLC / Johnson & Johnson / Pharmacyclics Inc. / Genmab A / Janssen Biotech Inc. / / Country United States / / Event Business Partnership / FDA Phase / / Facility National Cancer Institute / Janssen pipeline / / IndustryTerm health care products / healthcare solutions / / MedicalCondition cancers / cancer / multiple myeloma / disease / chronic lymphocytic leukemia / multiple myeloma cells / cardiovascular and metabolic diseases / Double Refractory Multiple Myeloma / infectious diseases / Multiple Myeloma Multiple myeloma / macroglobulinemia / refractory Mantle Cell Lymphoma / small lymphocytic lymphoma / / Organization National Cancer Institute / U.S. Food and Drug Administration / American Cancer Society / U.S. Government Printing Office / / Person Peter F. Lebowitz / Stan Panasewicz / Kellie McLaughlin / / / Position Global Oncology Therapeutic Area Head / Private / / Product CD38 / / PublishedMedium PUBLIC LAW / / Technology neuroscience / / URL www.sec.gov / http /
SocialTag |
Media Inquiries: Kellie McLaughlin Phone: Mobile: Investor Relations: Stan Panasewicz